Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
KURA– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin
KURASAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib) has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. Ltd. and Kyowa Kirin, Inc. (collectively, “Kyowa Kirin”), this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
KURA(NASDAQ:KURA) Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)
Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program
KURA(NASDAQ:KURA) September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
Kura Oncology to Participate in Three Upcoming Investor Conferences
KURASAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.
Kura Oncology And Kyowa Kirin Report Updated Clinical Data From KOMET-007, Phase 1a/1b Trial Of Ziftomenib, In Patients With Newly Diagnosed NPM1-M And KMT2A-R AML
KURAKura Oncology Grants Stock Options To 5 New Hires Covering 79,200 Shares As Employment Inducement
KURAJMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target
KURAKura Oncology And Kyowa Kirin Announce Phase 2 KOMET-001 Trial Results For Once-Daily Oral Menin Inhibitor Ziftomenib In Relapsed/Refractory NPM1-Mutated AML Showing 23% CR/CRh Rate, Durable MRD-Negative Responses Across Key Subgroups, Favorable Safety Wi
KURAReported Sunday, FDA Grants Priority Review To Kura And Kyowa Kirin's Ziftomenib NDA, Targeting First Menin Inhibitor Approval In NPM1-Mutant AML By November 30
KURAKura Oncology And Kyowa Kirin Reveal Monotherapy Data for Ziftomenib In Oral Presentation At The 2025 ASCO Annual Meeting
KURAMizuho Maintains Outperform on Kura Oncology, Lowers Price Target to $30
KURAKura Oncology And Kyowa Kirin Announce Combination Data For Ziftomenib In Oral Presentation At The 2025 EHA Congress
KURABarclays Maintains Overweight on Kura Oncology, Lowers Price Target to $11
KURAKura Oncology Q1 EPS $(0.66), Inline, Sales $14.11M Beat $7.73M Estimate
KURAUncovering Potential: Kura Oncology's Earnings Preview
KURAJMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $28 Price Target
KURAHC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target
KURAKura Oncology Submits New Drug Application (NDA) To The FDA For ziftomenib For The Treatment Of Acute Myeloid Leukemia (AML)
KURAKura Oncology to Present Kidney Cancer Drug Combo Data at AACR 2025
KURAKura Oncology Grants 190,000 Stock Options To Six New Employees As Inducement Awards
KURAUBS Maintains Buy on Kura Oncology, Lowers Price Target to $14
KURAHC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $40 Price Target
KURAKura Oncology Q4 GAAP EPS $(0.22) Beats $(0.65) Estimate, Sales $53.88M Beat $8.50M Estimate
KURAKura Oncology, Kyowa Kirin Enter Global Strategic Collaboration To Develop And Commercialize Ziftomenib; Kura To Receive $330M Upfront Payment And Up To $1.2B In Total Milestone Payments
KURAJMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
KURAHC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
KURACantor Fitzgerald Reiterates Overweight on Kura Oncology
KURAHC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
KURAKura Oncology To Present KOMET-007 Combination Trial Of Ziftomenib Data At ASH Annual Meeting
KURAJMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
KURAKura Oncology Q1 EPS $(0.49) Beats $(0.52) Estimate
KURA